<DOC>
	<DOCNO>NCT00867165</DOCNO>
	<brief_summary>The purpose study determine effect ezetimibe 10 mg/day compare placebo reduction low-density lipoprotein cholesterol ( LDL-C ) baseline 12 week treatment child &gt; =6 &lt; =10 year old primary hypercholesterolemia . The study also evaluate effect ezetimibe total cholesterol ( TC ) , apolipoprotein B ( Apo B ) , high-density lipoprotein cholesterol ( HDL-C ) , non-HDL-C , triglyceride ( TG ) . The safety ezetimibe subject population also evaluate .</brief_summary>
	<brief_title>Pediatric Study Evaluate Efficacy Safety Ezetimibe Monotherapy Children With Primary Hypercholesterolemia ( P05522 )</brief_title>
	<detailed_description />
	<mesh_term>Hypercholesterolemia</mesh_term>
	<mesh_term>Ezetimibe</mesh_term>
	<criteria>Each subject may either sex race/ethnicity , must &gt; =6 &lt; =10 year age , diagnosis primary hypercholesterolemia ( heterozygous familial nonfamilial ) despite lipidlowering diet least 3 month LDLC &gt; 159mg/dL Each subject 's parent/guardian must willing give write informed consent his/her behalf . Each subject must : Have know hypersensitivity contraindication ezetimibe . Have use investigational drug within 30 day study entry . Be member family member personnel investigational sponsor staff directly involve trial . Be female childbearing potential pregnant , intend become pregnant , nursing Have know congenital cardiac disorder . Have document laboratory value consistent homozygous familial hypercholesterolemia ( HoFH ) . Be know human immunodeficiency virus ( HIV ) positive .</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>10 Years</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>heterozygous familial hypercholesterolemia</keyword>
	<keyword>nonfamilial hypercholesterolemia</keyword>
</DOC>